Policy and perspectives

For MedTech manufacturers, the findings could shape evidence and access strategies for years to come.

Dr Bhakti Dhingra and Sami Agush break down what pharmaceutical companies need to know from the final rule and, more importantly, why it matters.

Murtaza Shahid explores how the strategic and operational priorities reinforced in NHS England's 2025/26 Annual Report may shape the future adoption of healthcare technologies.

Murtaza Shahid examines the expansion of independent prescribing through NHS Pharmacy First and discusses why the success of the policy may depend less on national ambition and more on local implementation.

Demetria-Ilinca Panait explores how the Netherlands is rethinking access and reimbursement for orphan medicines.

Ilinca Panait explores Operation TrialBlazer, a new Department of Health and Human Services initiative.

Dr Bhakti Dhingra, examines these recent changes in-depth, focusing on key elements such as the introduction of confidential reimbursement prices and the incentivisation of local clinical trials.

Priya Toor explores the recent proposals from the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ).

Nader Mourad explores the evolving role of outcomes-based agreements in mitigating MFN related pricing risks.

Nick Stringfellow takes the opportunity to explore the history of the disease and some of the major breakthroughs in treatment and prevention (along with overcoming their market access challenges) that have made the collective goal of eradicating the disease in the future more attainable.

These details signal a clear need for earlier planning, tighter coordination, and a more proactive approach to managing evidence and risk.

The first JCA for tovorafenib highlights a key reality: sparse PICO grids and limited comparative data may be the norm, not the exception, particularly in rare diseases.